A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

Description

The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate

Conditions

Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate

A Single-Center, Prospective Cohort Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

Condition
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Intervention / Treatment

-

Contacts and Locations

Foxboro

Neurology Center of New England P.C., Foxboro, Massachusetts, United States, 02035

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Signed informed consent
  • * Aged 55-80 years old
  • * Diagnosis of RMS according to the 2017 Revised McDonald criteria
  • * Anticipated to begin treatment with or newly treated with ublituximab (within 6 months prior to study entry) according to the local label
  • * Active participation in an interventional clinical trial for MS
  • * Received initial dose of ublituximab more than 6 months prior to study entry
  • * History of life-threatening infusion reaction on any anti-CD20 therapy
  • * Evidence of clinically significant chronic or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment, or any history of recurrent infection within 6-12 months prior to initiation of ublituximab

Ages Eligible for Study

55 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Neurology Center of New England P.C.,

Study Record Dates

2027-09-30